| 1. |
|
|
| 2. |
|
|
| 3. |
- Johansson, Annica, 1969, et al.
(författare)
-
CYP46A1 Variants Interact with Age and APOE to Influence CSF Aβ42 and Phospho-Tau Levels in Alzheimer's Disease
- 2004
-
Ingår i: The 9th International Conference on Alzheimer's Disease (ICAD), Philadelphia, Pennsylvania, USA, 20-25 July 2004.
-
Konferensbidrag (övrigt vetenskapligt/konstnärligt)abstract
- Recent studies have suggested that variants of CYP46A1, encoding cholesterol 24-hydroxylase (CYP46), confer risk to Alzheimer's disease (AD), a prospect substantiated by evidence of genetic association with several quantitative traits related to AD pathology, including cerebrospinal fluid (CSF) levels of the 42 amino-acid cleavage product of β-amyloid (Aβ42) and the tau protein. In the present study, these claims have been explored by the genotyping of previously associated markers in CYP46A1 in three independent Northern European case-control series encompassing 1323 individuals, which include approximately 400 patients with measures of CSF Aβ42 and phospho-tau protein levels. Tests of association in case-control models revealed limited evidence that CYP46A1 variants contribute to AD risk across these samples. However, models testing for potential effects upon CSF measures suggested possible interaction of an intronic marker (rs754203) with age and APOE genotype. In stratified analyses, significant effects were evident that were restricted to elderly APOE ε4 carriers for both CSF Aβ42 (P = 0.0009) and phospho-tau (P = 0.046). Computational analyses indicate that the rs754203 marker probably does not impact the binding of regulatory factors, suggesting that other polymorphic sites underlie observed associations. Results provide an important independent replication of previous findings, supporting the existence of CYP46A1 sequence variants that contribute to variability in β-amyloid metabolism.
|
|
| 4. |
- Johansson, Annica, 1969, et al.
(författare)
-
Identification of polymorphic sites in the CDC2 gene, a possible susceptibility gene for Alzheimer's disease located on chromosome 10
- 2002
-
Ingår i: The 8th International Conference on Alzheimer's Disease and Related Disorders, Stockholm 20-25 July 2002.
-
Konferensbidrag (övrigt vetenskapligt/konstnärligt)abstract
- The human cdc2, which is required in the mitotic cell cycle, has recently been associated with Alzheimer’s disease (AD). Cdc2 has also been shown to phosphorylate all of tau protein, β-amyloid and amyloid precursor protein (APP) both in vitro and in vivo. Inappropriate activation of cdc2 kinase in differentiated neurons has been suggested to contribute to neuronal dysfunction and degeneration in AD. The cdc2 gene maps to chromosome 10q, which recently has been found to be a susceptibility locus for AD, which makes the cdc2 gene a possible candidate gene for AD. To investigate whether the cdc2 gene contains polymorphic sites we sequenced the promoter region and the seven coding exons and flanking introns in 14 AD cases and 8 controls. We found several variations in the promoter region and three polymorphic sites in the intron between exon 6 and 7, one of these located in the 5’-splice site of exon 6. Data will be presented on the frequency of these polymorphisms in large series of AD patients and controls.
|
|
| 5. |
- Johansson, Annica, 1969, et al.
(författare)
-
Variants of CYP46A1 may interact with age and APOE to influence CSF Abeta42 levels in Alzheimer's disease.
- 2004
-
Ingår i: Human genetics. - : Springer Science and Business Media LLC. - 0340-6717 .- 1432-1203. ; 114:6, s. 581-7
-
Tidskriftsartikel (refereegranskat)abstract
- Recent studies have suggested that variants of CYP46A1, encoding cholesterol 24-hydroxylase (CYP46), confer risk for Alzheimer's disease (AD), a prospect substantiated by evidence of genetic association from several quantitative traits related to AD pathology, including cerebrospinal fluid (CSF) levels of the 42 amino-acid cleavage product of beta-amyloid (Abeta42) and the tau protein. In the present study, these claims have been explored by the genotyping of previously associated markers in CYP46A1 in three independent northern European case-control series encompassing 1323 individuals and including approximately 400 patients with measurements of CSF Abeta42 and phospho-tau protein levels. Tests of association in case-control models revealed limited evidence that CYP46A1 variants contributed to AD risk across these samples. However, models testing for potential effects upon CSF measures suggested a possible interaction of an intronic marker (rs754203) with age and APOE genotype. In stratified analyses, significant effects were evident that were restricted to elderly APOE epsilon4 carriers for both CSF Abeta42 ( P=0.0009) and phospho-tau ( P=0.046). Computational analyses indicate that the rs754203 marker probably does not impact the binding of regulatory factors, suggesting that other polymorphic sites underlie the observed associations. Our results provide an important independent replication of previous findings, supporting the existence of CYP46A1 sequence variants that contribute to variability in beta-amyloid metabolism.
|
|
| 6. |
- McCaddon, Andrew, et al.
(författare)
-
Transcobalamin polymorphism and serum holo-transcobalamin in relation to Alzheimer's disease
- 2004
-
Ingår i: Dementia and Geriatric Cognitive Disorders. - : S. Karger AG. - 1420-8008 .- 1421-9824. ; 17:3, s. 215-221
-
Tidskriftsartikel (refereegranskat)abstract
- Isoforms of the vitamin B<sub>12</sub> carrier protein transcobalamin (TC) might influence its cellular availability and contribute to the association between disrupted single-carbon metabolism and Alzheimer’s disease (AD). We therefore investigated the relationships between the TC 776C>G (Pro259Arg) genetic polymorphism, total serum cobalamin and holo-TC levels, and disease onset in 70 patients with clinically diagnosed AD and 74 healthy elderly controls. TC 776C>G polymorphism was also determined for 94 histopathologically confirmed AD patients and 107 controls. Serum holo-TC levels were significantly higher in TC 776C homozygotes (p = 0.04). Kaplan-Meier survival functions differed between homozygous genotypes (Cox’s F-Test F(42, 46) = 2.1; p = 0.008) and between 776C homozygotes and heterozygotes (Cox’s F test F(46, 108) = 1.7; p = 0.02). Proportionately fewer TC 776C homozygotes appear to develop AD at any given age, but this will require confirmation in a longitudinal study.
|
|
